European Rare Disease ‘Moonshot’ Coalition Targets Unmet Needs & Innovation
Executive Summary
The members of a new group aiming to boost rare disease R&D say that Europe needs a “solid pro-innovation ecosystem” supported by a stable intellectual property framework and a “world-class” regulatory system.
You may also be interested in...
Rare Diseases: European Market Access ‘Better Organized’ Than US, Says Rhythm
Rhythm is working with country-level authorities and centers of excellence in Europe to gain reimbursement and access for its obesity treatment Imcivree.
EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season
The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination.
Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.